Health and Me

Ishita Srivastava

DengiAll, India's First Dengue Vaccine Clears Phase III Trials, May Soon Enter Markets

DengiAll, India's first indigenous <a href="https://www.healthandme.com/health/dengue">dengue</a> vaccination, has completed its Phase-III human trials across 19 locations in India and is now waiting for final approval before being distributed across the country.

The vaccine, which has been in development since 2008 and is set to hit shelves in 2027, is a single dose medication that protects patients from all four variants of dengue fever.

Made by Panacea Biotec with technology from the US National Institutes of Health (NIH), the vaccine aims to provide long-term immunity and reduce the significant public health burden of dengue fever in India and globally.

Dr Syed Khalid Ali, Chief Scientific Officer at Panacea Biotec told <a href="https://theprint.in/ground-reports/indias-first-dengue-vaccine-has-been-in-the-making-for-17-yrs-dengiall-has-the-world-excited/2820310/" data-type="tilCustomLink" rel="noopener nofollow noreferrer" target="_blank" rel= "noopener nofollow noreferrer" target= "_blank">The Print</a>, "Dengue has puzzled scientists and immunologists for decades now. People infected with it can show anything from mild flu-like symptoms to even death. A lot of it has to do with the serotypes of dengue, and how they interact with each other.

"DengiAll has been in the making for over 15 years, and it comes at a time when half the world’s population is at risk of dengue. There’s no question about need. We needed such a vaccine yesterday.”

DengiAll works by using live, weakened versions of all four dengue virus types (DEN1, DEN2, DEN3 and DEN4) in a single shot to train the immune system to recognize and fight all variants of the virus and and protect the body from future natural infections. 

The vaccine is also a tetravalent vaccine meaning that it is designed to provide balanced immunity against all four variants and overcome the challenge of each of the different types, making it a crucial feature as getting a second dengue infection with a different serotype can be more severe and deadly.

Dr Ali explains, "The catch is, if you get infected with one serotype, you’re only protected from that one type. You can very likely get infected with dengue again, with another serotype. In fact, the second infection is more likely to be severe, even life-threatening."

Transmitted by Aedes mosquitoes, dengue presents with high fever, headache, joint pain and rash, and while often severe forms can be fatal. Over the years,

the mosquito-borne disease has become a major public health concern in India, ranking among the top 30 countries with the highest incidence of the disease.

States such as Karnataka, Tamil Nadu, and Maharashtra often report high case numbers annually after monsoons due to climate change, urbanization, and multiple virus strains. According to Global HealthCare Academy, around 1.5 to 2 lakh people fall sick from it every year. 

The global incidence of dengue has been steadily increasing over the past two decades, with more than 129 countries reporting dengue viral disease by the end of 2023, according to the World Health Organization.

Apart from DengiAll, Butantan-DV is the only other single-dose, live-attenuated dengue vaccine approved in Brazil for ages 12-59 and is expected to rollout in 2026. <ul></ul>

Health Conditions A-Z

health

dengue

panacea biotec

world health organization

DengiAll

vaccine

Genelia D'Souza Reveals She Keeps Ghee Away From Her Kids, Claims It  ‘Blocks Their Arteries’

COVID Symptoms 2026: Study Maps Common Symptom Patterns Seen In Long COVID Patients

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

DengiAll, India's first indigenous dengue vaccination, has completed its Phase-III human trials across 19 locations in India and is now waiting for final approval before being distributed across the country.The vaccine, which has been in development since 2008 and is set to hit shelves in 2027, is a single dose medication that protects patients from all four variants of dengue fever. Made by Panacea Biotec with technology from the US National Institutes of Health (NIH), the vaccine aims to provide long-term immunity and reduce the significant public health burden of dengue fever in India and globally. Dr Syed Khalid Ali, Chief Scientific Officer at Panacea Biotec told The Print, "Dengue has puzzled scientists and immunologists for decades now. People infected with it can show anything from mild flu-like symptoms to even death. A lot of it has to do with the serotypes of dengue, and how they interact with each other."DengiAll has been in the making for over 15 years, and it comes at a time when half the world’s population is at risk of dengue. There’s no question about need. We needed such a vaccine yesterday.”How Does It Work?DengiAll works by using live, weakened versions of all four dengue virus types (DEN1, DEN2, DEN3 and DEN4) in a single shot to train the immune system to recognize and fight all variants of the virus and and protect the body from future natural infections. The vaccine is also a tetravalent vaccine meaning that it is designed to provide balanced immunity against all four variants and overcome the challenge of each of the different types, making it a crucial feature as getting a second dengue infection with a different serotype can be more severe and deadly.Dr Ali explains, "The catch is, if you get infected with one serotype, you’re only protected from that one type. You can very likely get infected with dengue again, with another serotype. In fact, the second infection is more likely to be severe, even life-threatening."Why Is This Vaccine Necessary?Transmitted by Aedes mosquitoes, dengue presents with high fever, headache, joint pain and rash, and while often severe forms can be fatal. Over the years, the mosquito-borne disease has become a major public health concern in India, ranking among the top 30 countries with the highest incidence of the disease.States such as Karnataka, Tamil Nadu, and Maharashtra often report high case numbers annually after monsoons due to climate change, urbanization, and multiple virus strains. According to Global HealthCare Academy, around 1.5 to 2 lakh people fall sick from it every year. The global incidence of dengue has been steadily increasing over the past two decades, with more than 129 countries reporting dengue viral disease by the end of 2023, according to the World Health Organization.Apart from DengiAll, Butantan-DV is the only other single-dose, live-attenuated dengue vaccine approved in Brazil for ages 12-59 and is expected to rollout in 2026. 